Fairvalue-Calculator Fairvalue-Calculator
EN DE

Beijing Succeeder Technology Inc (688338) Fair Value & Analysis

Healthcare · CN · Market cap 2.6B CNY

Price¥26.90
Fair Value¥18.06
Upside-32.9%
Quality95/100
Evidence: High Range ¥14.62 – ¥22.58

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Beijing Succeeder Technology Inc (688338) currently trades at ¥26.90, while our model-based Fair Value estimate is ¥18.06 — implying the stock looks roughly 32.9% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Beijing Succeeder Technology Inc. engages in the research and development, manufacture, and sale of in-vitro diagnostic products in China and internationally. The company offers coagulation testers, hemorheology testers, erythrocyte sedimentation testers, platelet aggregation testers, diagnostic reagents, quality control products. Its products are used in the prevention, screening, diagnosis, and monitoring of thrombophilia, coronary heart disease, venous thromboembolism, and other thrombotic and bleeding disorders. Beijing Succeeder Technology Inc. was founded in 2003 and is based in Beijing, China.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is Beijing Succeeder Technology Inc (688338) undervalued?
As of Jun 24, 2026, our model estimates a fair value of ¥18.06 versus a price of ¥26.90 — about −33% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 688338?
Our 21-model fair value for Beijing Succeeder Technology Inc is ¥18.06 (as of Jun 24, 2026), built from audited fundamentals. The current price is ¥26.90.
What is the quality score of 688338?
Beijing Succeeder Technology Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.